Shares in Movetis NV edged up slightly on their first day of trading on the NYSE Euronext Exchange in Brussels Friday, following an IPO that raised gross proceeds of €85 million (US$126 million). The company priced the offering of 6,938,776 new shares at €12.25, slightly below the mid-point of the indicative range of €11.25 to €14.25 it published at the outset of the book-building period. (BioWorld International)
Shares in Bavarian Nordic A/S dropped more than 3 percent Tuesday on news that the company is planning to raise DKK250 million (US$50.6 million) to DKK300 million early in the new year. (BioWorld International)
No Abstract BioWorld International CorrespondentWilex AG delayed completion of a capital increase because of the early arrival of positive preliminary data from a Phase III trial of its diagnostic antibody Redectane, which is in development for presurgical detection of clear cell renal cell carcinoma, the most common form of kidney cancer.
Shares in Clavis Pharma ASA soared on the Oslo Bors Tuesday, on news that it licensed its Phase II pancreatic cancer drug CP-4126 to Clovis Oncology Inc., for an up-front payment of $15 million, plus a potential $365 million in development, regulatory and sales-related milestones. (BioWorld Today)
No Abstract BioWorld International CorrespondentMovetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.With a European product launch imminent, the company offers a far less risky proposition than most, however.
No Abstract BioWorld International CorrespondentCellerix raised €27 million (US$40.6 million) in the first closing of a new investment round, which it aims to expand to €35 million by year-end.
